ONMD:NASDAQOneMedNet Corp Analysis

OneMedNet (ONMD) trades at $0.888, sitting just above its 20‑day SMA ($0.876) and 50‑day SMA ($0.783) but well below the 200‑day SMA ($1.10), indicating a short‑term bounce within a longer‑term downtrend. The RSI of 53 is neutral, while the MACD shows a bearish signal with a negative histogram, and volume has been decreasing, suggesting limited buying pressure. Volatility is extremely high at ~86% and the stock has suffered an 81% max drawdown, underscoring significant price risk. Fundamentally, the company reports a 329% revenue jump to $1.25 M in 2025, driven by AI‑enabled real‑world data and new collaborations with Onco‑Innovations and Inka Health, yet margins remain deeply negative (gross margin –37%, operating margin –3.5%) and cash flow is strongly negative. The balance sheet shows $585 K cash versus $974 K debt, with a negative book value per share (‑$0.057) and a price‑to‑sales of 34×, implying the stock is priced far above its current earnings power. No dividend is paid, and the PB ratio of –15.6 signals an overvalued position relative to book. The beta of ~1.03 suggests market‑aligned price movements, but the combination of high volatility, weak profitability, and a speculative growth narrative heightens overall risk.